PEER Trial: Part 2 Rice Technologies

Description

The study aims to compare the accuracy of the lateral flow test to detect HPV at the POC with commercially available HPV test and to determine the diagnostic accuracy and reliability of a multimodal optical imaging system to detect cervical dysplasia, with the gold reference standard of histopathology.

Conditions

Cervical Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The study aims to compare the accuracy of the lateral flow test to detect HPV at the POC with commercially available HPV test and to determine the diagnostic accuracy and reliability of a multimodal optical imaging system to detect cervical dysplasia, with the gold reference standard of histopathology.

Assessment of New Technologies for the Screening and Diagnosis of Cervical Cancer in Mozambique, A Study to be Conducted in Maputo Central Hospital, Mavalane and Jose Macamo General Hospitals and Mavalane Health Center

PEER Trial: Part 2 Rice Technologies

Condition
Cervical Cancer
Intervention / Treatment

-

Contacts and Locations

Houston

M D Anderson Cancer Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. 25 - 49 year old women
  • 2. Women with a positive cervical cancer screening test (abnormal cytology, positive VIA and/or positive HPV test)
  • 3. Women with intact cervix
  • 4. Women who are not pregnant and with a negative pregnancy test (within 14 days from the date of enrollment) ) and not currently breastfeeding
  • 5. Willing and capable of providing informed consent
  • 1. Women under 25 or over 49 years old
  • 2. Women who have undergone a total hysterectomy (with removal of the cervix)
  • 3. Women who are pregnant or breastfeeding

Ages Eligible for Study

25 Years to 49 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

M.D. Anderson Cancer Center,

Kathleen Schmeler, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

2028-03-30